SciSparc Ltd. (SPRC) stock
SPRCNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.36−0.04 (-10.77%)
Close on Nov 12, 2026Market cap $129.84KP/E 0.0Yield –
SciSparc EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
For fiscal 2025 it was $98.07, down 51.9% from the year before. Over ten years it grew 16.8% a year on average. The highest annual figure on record is $13906.62 in fiscal 2021.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $98.07 | -51.9% |
| FY2024 | Dec 31, 2024 | $203.89 | -91.4% |
| FY2023 | Dec 31, 2023 | $2374.55 | -15.2% |
| FY2022 | Dec 31, 2022 | $2800.98 | -79.9% |
| FY2021 | Dec 31, 2021 | $13906.62 | +66790.9% |
| FY2020 | Dec 31, 2020 | $20.79 | -82.8% |
| FY2019 | Dec 31, 2019 | $120.96 | -46.7% |
| FY2018 | Dec 31, 2018 | $226.80 | +2300.0% |
| FY2017 | Dec 31, 2017 | $9.45 | 0.0% |
| FY2016 | Dec 31, 2016 | $9.45 | -54.5% |
| FY2015 | Dec 31, 2015 | $20.79 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2018 | Jun 30, 2018 | $1.89 | – |
| Q2 FY2017 | Jun 30, 2017 | $5.67 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?